Oorja Bio Initiated Phase 2 Clinical Trial
The company began the first patient screening for its study on the idiopathic pulmonary fibrosis drug ORJ-001.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you believe new medical research is successfully improving outcomes for people with terminal illnesses?
Houston-based Oorja Bio has initiated a Phase 2 clinical trial for its drug candidate ORJ-001 to treat idiopathic pulmonary fibrosis. The first patient has been screened for the ORBIT-IPF study, a randomized, double-blind, placebo-controlled trial.
Why it matters
The study aims to assess the safety, tolerability, and efficacy of ORJ-001, a peptide therapeutic designed to target alveolar epithelial type 2 cells. This research seeks to provide new treatment options for a condition that carries a life expectancy of only three to five years.
The clinical trial is a multicenter study evaluating ORJ-001 through a 12-week treatment duration in Part A. Patients in the study receive subcutaneous injections of the peptide therapeutic twice weekly.
The players
Oorja Bio
A Houston-based biotechnology company focused on developing peptide therapeutics for respiratory diseases.
The details
Oorja Bio is utilizing an adaptive study design that tracks biomarkers of fibrosis and epithelial damage in participants. This approach is intended to provide a rigorous evaluation of how the peptide therapeutic interacts with cellular targets in patients with the disease.
Timeline
October 13, 2026: Oorja Bio announced the initiation of the clinical trial.
The Big Picture
The initiation of the ORBIT-IPF study marks a shift toward specialized peptide therapeutics in the treatment of pulmonary fibrosis. This discovery path moves the field away from non-specific interventions toward therapies targeting the alveolar epithelial type 2 cells.
The trial progress offers a potential future treatment pathway for patients currently limited by the disease's poor life expectancy. Participants and their healthcare providers should monitor trial progress for findings related to drug safety and efficacy.
The takeaway
This trial represents a significant milestone for patients struggling with idiopathic pulmonary fibrosis. Stakeholders and families should follow updates from clinical trials to understand how new peptide therapies might evolve current standards of care.
Further reading
Learn more about the latest developments in the sector at the Biotech section.
More information
For more information, visit the clinical trial information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new medical research is successfully improving outcomes for people with terminal illnesses?
